Dopamine and Insulin Resistance
NCT00802204 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28
Last updated 2017-05-10
Summary
Obese individuals have fewer striatal dopamine type 2 receptors (DRD2) than normal weight individuals. Lower DRD2 levels are associated with addiction and a decreased sense of pleasure.Obesity is also associated with insulin resistance (poor insulin action).We propose that insulin resistance and low DRD2 are associated. Using PET imaging,we aim to determine DRD2 binding potential (BP) in the brain is associated with insulin resistance and neuroendocrine hormone levels. Obese participants will be compared to lean, gender and age similar participants. We also aim to determine the effect of caloric restriction on DRD2 BP in obese subjects
Conditions
Interventions
- RADIATION
-
PET scan
Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride \[18F\] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet. Completed at baseline and post-VLCD
- PROCEDURE
-
Oral glucose tolerance test
Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD
- PROCEDURE
-
MRI
An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese
- BEHAVIORAL
-
Psychological scales to assess attitudes and behaviors related to eating and quality of life
A series of short psychological scales will be administered during the study. Completed at baseline
- OTHER
-
Caloric Restriction
Obese participants only complete a short-term (\~10days) very low calorie diet
Sponsors & Collaborators
-
Vanderbilt University
lead OTHER
Principal Investigators
-
Julia P Dunn, MD · Vanderbilt University Medical Center
-
Robert M Kessler, MD · Vanderbilt University Medical Center
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- OTHER
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-12-31
- Primary Completion
- 2011-04-30
- Completion
- 2012-12-31
Countries
- United States
Study Locations
More Related Trials
-
The Role of Apathy in Glycemic Control
NCT00844090 ·Status: COMPLETED ·Phase: NA
-
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans
NCT00625014 ·Status: COMPLETED ·Phase: NA
-
Endogenous Opioid Activity and Affective State in Insulin Resistant Women
NCT02069379 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Ghrelin Administration on Dopamine and Effort
NCT05318924 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dopamine and Insulin in Psychosis
NCT07252752 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects
NCT01103726 ·Status: COMPLETED ·Phase: PHASE1
-
Brain Insulin Resistance in Mood Disorders
NCT03915613 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Glucose and Lipid Metabolism on Antipsychotic Medication
NCT00515723 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes
NCT01281228 ·Status: COMPLETED ·Phase: NA
-
Diabetes in Neuropsychiatric Disorders
NCT00446992 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Dopamine Action on Metabolism in Relation to Genotype
NCT03525002 ·Status: COMPLETED ·Phase: PHASE2
-
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
NCT05748990 ·Status: RECRUITING ·Phase: NA
-
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
NCT02796144 ·Status: TERMINATED ·Phase: PHASE4
-
Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
NCT01160991 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
NCT00451399 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Atypical Antipsychotic and Valproate Combination Therapy on Glucose and Lipid Metabolism in Schizophrenia
NCT00552500 ·Status: COMPLETED ·Phase: NA
-
Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics
NCT01411930 ·Status: COMPLETED ·Phase: PHASE4
-
Weight Management Program for Patients With First Episode Psychosis
NCT05207982 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity
NCT00339014 ·Status: COMPLETED ·Phase: PHASE2
-
An Insulin Sensitivity Study in Healthy Subjects
NCT02922426 ·Status: COMPLETED ·Phase: PHASE1
-
A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers
NCT00741026 ·Status: COMPLETED ·Phase: NA
-
Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect?
NCT07109245 ·Status: RECRUITING ·Phase: PHASE4
-
Metformin for Treatment of Antipsychotic-induced Dyslipidemia
NCT01778244 ·Status: COMPLETED ·Phase: PHASE4
-
Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)
NCT00790517 ·Status: COMPLETED ·Phase: PHASE2
-
Molecular Mechanisms of Antipsychotic-induced Insulin Resistance
NCT02708394 ·Status: COMPLETED ·Phase: EARLY_PHASE1